Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Serotonin 2A receptor antagonists for treatment of schizophrenia.

Ebdrup BH, Rasmussen H, Arnt J, Glenthøj B.

Expert Opin Investig Drugs. 2011 Sep;20(9):1211-23. doi: 10.1517/13543784.2011.601738. Epub 2011 Jul 8. Review.

PMID:
21740279
2.

ACS chemical neuroscience molecule spotlight on Fanapt.

Hopkins CR.

ACS Chem Neurosci. 2010 Jun 16;1(6):410. doi: 10.1021/cn100024g. Review.

3.
4.

Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.

Gacsályi I, Nagy K, Pallagi K, Lévay G, Hársing LG Jr, Móricz K, Kertész S, Varga P, Haller J, Gigler G, Szénási G, Barkóczy J, Bíró J, Spedding M, Antoni FA.

Neuropharmacology. 2013 Jan;64:254-63. doi: 10.1016/j.neuropharm.2012.07.017. Epub 2012 Jul 21.

PMID:
22824189
5.

Involvement of 5-HT2A receptor and α2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow.

Frånberg O, Marcus MM, Svensson TH.

Synapse. 2012 Jul;66(7):650-60. doi: 10.1002/syn.21551. Epub 2012 Mar 16.

PMID:
22362425
6.

Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo.

Yadav PN, Kroeze WK, Farrell MS, Roth BL.

J Pharmacol Exp Ther. 2011 Oct;339(1):99-105. doi: 10.1124/jpet.111.183780. Epub 2011 Jul 7.

7.

Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.

Kuroki T, Nagao N, Nakahara T.

Prog Brain Res. 2008;172:199-212. doi: 10.1016/S0079-6123(08)00910-2. Review.

PMID:
18772034
8.

Impulsive action induced by amphetamine, cocaine and MK801 is reduced by 5-HT(2C) receptor stimulation and 5-HT(2A) receptor blockade.

Fletcher PJ, Rizos Z, Noble K, Higgins GA.

Neuropharmacology. 2011 Sep;61(3):468-77. doi: 10.1016/j.neuropharm.2011.02.025. Epub 2011 Mar 21.

PMID:
21402085
9.

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.

Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U.

Schizophr Res. 2012 Nov;141(2-3):144-52. doi: 10.1016/j.schres.2012.07.029. Epub 2012 Sep 4.

10.

Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats.

Wadenberg MG, Browning JL, Young KA, Hicks PB.

Pharmacol Biochem Behav. 2001 Mar;68(3):363-70.

PMID:
11325387
11.

Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients.

Erritzoe D, Rasmussen H, Kristiansen KT, Frokjaer VG, Haugbol S, Pinborg L, Baaré W, Svarer C, Madsen J, Lublin H, Knudsen GM, Glenthoj BY.

Neuropsychopharmacology. 2008 Sep;33(10):2435-41. doi: 10.1038/sj.npp.1301656. Epub 2008 Feb 20.

12.

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.

Meltzer HY, Huang M.

Prog Brain Res. 2008;172:177-97. doi: 10.1016/S0079-6123(08)00909-6. Review.

PMID:
18772033
13.

High 5HT2A receptor occupancy in M100907-treated schizophrenic patients.

Talvik-Lotfi M, Nyberg S, Nordström AL, Ito H, Halldin C, Brunner F, Farde L.

Psychopharmacology (Berl). 2000 Mar;148(4):400-3.

PMID:
10928313
14.

Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.

Roth BL, Hanizavareh SM, Blum AE.

Psychopharmacology (Berl). 2004 Jun;174(1):17-24. Epub 2003 Dec 2. Review.

PMID:
15205874
15.

Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET).

Hodé Y, Benyamina A, Arbus C, Reimold M.

Psychopharmacology (Berl). 2011 Oct;217(3):315-21. doi: 10.1007/s00213-011-2289-1. Epub 2011 Apr 9.

PMID:
21479533
16.

Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.

Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H.

Psychopharmacology (Berl). 2007 Feb;190(2):241-9. Epub 2006 Nov 17.

PMID:
17111172
17.

Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy.

Knauer CS, Campbell JE, Galvan B, Bowman C, Osgood S, Buist S, Buchholz L, Henry B, Wong EH, Shahid M, Grimwood S.

Eur J Pharmacol. 2008 Sep 4;591(1-3):136-41. doi: 10.1016/j.ejphar.2008.06.063. Epub 2008 Jun 19.

PMID:
18593577
18.

Evaluation of dopamine D₂/D₃ and serotonin 5-HT₂A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography.

Nakazawa S, Yokoyama C, Nishimura N, Horisawa T, Kawasaki A, Mizuma H, Doi H, Onoe H.

Psychopharmacology (Berl). 2013 Jan;225(2):329-39. doi: 10.1007/s00213-012-2815-9. Epub 2012 Aug 7.

PMID:
22868411
19.

Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.

Meltzer HY, Massey BW, Horiguchi M.

Curr Pharm Biotechnol. 2012 Jun;13(8):1572-86. Review.

PMID:
22283753
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk